Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
FCE 28260
Подписчиков: 0, рейтинг: 0
Clinical data | |
---|---|
Other names | PNU 156765 |
Routes of administration |
Oral |
ATC code |
|
Identifiers | |
| |
CAS Number | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C28H35F3N2O2 |
Molar mass | 488.595 g·mol−1 |
3D model (JSmol) | |
| |
|
FCE 28260 is an azasteroidal 5α-reductase inhibitor which was developed for the treatment of benign prostatic hyperplasia and androgenic alopecia (pattern hair loss) in the 1990s but was never marketed. FCE 28260 has been found to inhibit rat and human 5α-reductase with half-maximal inhibitory concentrations (IC50) of 15 and 16 nM, respectively, while finasteride had values of 30 and 52 nM.